Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297710 | 0.88 | HRH2 (0.43) | ALDH1A1KDM1AKDM4EMAPTHRH2 | |
| SCHEMBL4508388 | 0.86 | HRH2 (0.42) | ALDH1A1KDM1AKDM4EMAPTHRH2 | |
| SCHEMBL10436830 | 0.83 | ALDH1A1 (0.51) | ALDH1A1KDM4ENPSR1SMN1; SMN2MEN1 | |
| SCHEMBL26031772 | 0.82 | ALDH1A1 (0.46) | ALDH1A1KDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL12244537 | 0.82 | CYP2D6 (0.44) | ALDH1A1KDM1AKDM4EMAPTTDP1 | |
| Ethane SCHEMBL3270216 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KDM4EMAPTNPSR1MEN1 | |
| SCHEMBL1098206 | 0.80 | KDM1A (0.45) | ALDH1A1KDM1AKDM4EMAPTHRH2 | |
| SCHEMBL2721148 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KDM4EMAPTNPSR1CYP2D6 | |
| SCHEMBL10262951 | 0.80 | MEN1 (0.46) | ALDH1A1KDM1AKDM4EHRH2HRH1 | |
| SCHEMBL5760699 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KDM4EMAPTNPSR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9399635-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2016-07-26 | — | — | US | claimed |
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PHARMA EIGHT CO., LTD. (JP) | 2014-03-27 | — | — | US | claimed |
| EP-2698368-A1 | NOVEL PYRAZOLE DERIVATIVE | Pharma Eight Co. Ltd (JP) | 2014-02-19 | — | — | EP | claimed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | claimed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | claimed |
| EP-1562955-B1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| EP-1802591-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | claimed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | claimed |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| WO-2004108707-A1 | PYRIDAZINIL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| WO-2004108711-A1 | PYRAZINIL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| WO-2004108710-A1 | 4-PYRIMIDINYL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| WO-2004108704-A1 | PYRIMIDIN-4-YL 3-CYANOQUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| WO-2004069827-A1 | QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | claimed |
| WO-2004069249-A1 | 3-CYANO-QUINOLINE DERIVATIVES AS NON-RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | claimed |
| WO-2004069250-A1 | 3-CYANO-QUINOLINE DERIVATIVES AS NON-RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | claimed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | claimed |
| WO-2003047585-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BENZOFURANYL SUBSTITUTED 3-CYANOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SOLID TUMOURS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | claimed |
| WO-2003048159-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | ALDH1A1 2449/4885KDM1A 1715/4885KDM4E 2349/4885 |
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | ALDH1A1 2094/4885KDM1A 2179/4885KDM4E 2801/4885 |
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PSEN2, MAPT, PSEN1 | ALDH1A1 675/4885KDM1A 1414/4885KDM4E 3193/4885 |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | SRC, ABL1, ERBB2 | ALDH1A1 3374/4885KDM1A 326/4885KDM4E 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.